Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review-Reference-Cited by-同舟云学术

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review

Published:2016-04-02 Issue:2 Volume:48 Page:266-280
ISSN:0360-2532
Container-title:Drug Metabolism Reviews
language:en
Short-container-title:Drug Metabolism Reviews

Author:

Nijenhuis C. M.¹,Schellens J. H. M.²³,Beijnen J. H.¹³

Affiliation:

1. Department of Pharmacy & Pharmacology, Antoni Van Leeuwenhoek/the Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands;

2. Department of Medical Oncology, Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;

3. Department of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Utrecht University, Utrecht, The Netherlands

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Link

https://www.tandfonline.com/doi/pdf/10.1080/03602532.2016.1181081

Reference80 articles.

1. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects

2. Accelerator mass spectrometry-enabled studies: current status and future prospects

3. Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials

4. Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man

5. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans;European Journal of Drug Metabolism and Pharmacokinetics;2023-10-13

2. A phase I, single‐center, open‐label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [¹⁴C] encorafenib in healthy male subjects;Pharmacology Research & Perspectives;2023-09-29

3. Study of the mass balance, biotransformation and safety of [14C]SHR8554, a novel μ-opioid receptor injection, in healthy Chinese subjects;Frontiers in Pharmacology;2023-09-14

4. Human radiolabeled mass balance studies supporting the FDA approval of new drugs;Clinical and Translational Science;2022-09-23

5. Late-Stage Carbon-14 Labeling and Isotope Exchange: Emerging Opportunities and Future Challenges;JACS Au;2022-06-07